A randomized Phase 3 clincal trial has concluded that combining bortezomib (Velcade) with pegylated liposomal doxorubicin (PLD) does not show benefit in treating relapsed or refractory…
Many patients with blood cancers, such as myeloma, go into remission after receiving a stem-cell transplant. However, there are still many patients (about one-third) who relapse, a condition…
A study has uncovered that elevated body mass index (BMI), a measurement of obesity, increases an individual’s risk of developing multiple myeloma and the disease’s…
Researchers at the University of Birmingham have found that blocking a specific mechanism in the benign condition monoclonal gammophaty of undetermined significance (MGUS) may prevent the development…
In the largest study to date, researchers from The Institute of Cancer Research in London identified eight new gene mutations increasing the risk of developing…
Global biotech firm Amgen has announced that the European Commission (EC) approved a variation to the marketing authorization for Kyprolis (carfilzomib) to be used in combination with…
Advances in the molecular understanding of multiple myeloma (MM) onset and disease development have enabled the production of effective drugs, such as bortezomib,thalidomide, and lenalidomide,…
Results from a clinical trial support the use of a specific combination drug induction therapy over another three-drug treatment in multiple myeloma patients who are eligible…
Takeda Pharmaceutical Company Limited has recently received a negative opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…
The Advanced Practitioners Society for Hematology and Oncology (APSHO) is presenting a series of live continuing medical education (CME) meetings, titled the “APSHO Regional Lecture…